



November 12, 2014

Integra LifeSciences Introduces Integra(R) Pocket Strip and Integra(R) Shaped Strip DBM Implants

Company's First DBM Implants Specifically Designed for Posterior Lumbar Spine Fusion Procedures

PLAINSBORO, N.J., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the limited market release of a new orthobiologic implant. The Demineralized Bone Matrix (DBM) Strip implant is used primarily for posterior lumbar fusion, a surgical procedure intended to promote bone fusion along the posterior elements of the spine. Integra's newest orthobiologic implant, distributed by Integra's subsidiary IsoTis OrthoBiologics, will be featured at the North American Spine Society (NASS) 29th annual meeting, November 12 - 15, 2014 in San Francisco, California.

Available in two forms, the Integra[®] Shaped Strip and Integra[®] Pocket Strip are 100% human allograft, providing a natural biologic scaffold with verified osteoinductive* potential. The implant features a deep recess designed to accommodate placement of additional graft material. When hydrated, the graft is pliable, maintains integrity upon irrigation, and can be contoured to varying patient anatomy.

"We're very excited to add these new implants to Integra's orthobiologic product portfolio. This not only addresses an identified market need, but is Integra's first DBM implant designed for a specific surgical procedure. The new implant also expands our biologics footprint and strengthens our overall position in the spine market," said John Winge, Vice President Sales, U.S. Spine.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics. For more information, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

**DBM or representative finished implant is either assayed in vivo in the modified athymic nude rat for bone formation or in vitro for endogenous BMP-2 as a surrogate test marker for osteoinductive potential. Because the combination of various proteins is responsible for osteoinductive potential, DBM when assayed invitro, is also screened for the presence of BMP-7. Findings from an in vitro assay or animal model are not necessarily predictive of human clinical results.*

CONTACT: Integra LifeSciences:

Media

Gianna Sabella

609-936-2389

gianna.sabella@integralife.com

Investors

Angela Steinway

609-936-2268

angela.steinway@integralife.com